The Clinical Utility of Biochemical Biomarkers in Colorectal Cancer
نویسندگان
1 Department of Clinical Biochemistry, Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran
2 Department of Biochemistry, Payame Noor University, Tehran, Iran
3 Non-communicable Diseases Institute, Gut and Liver Research Center, Mazandaran University of Medical Sciences, Sari, Iran
4 Department of Food and Drug Deputy, Mazandaran University of Medical Sciences, Sari, Iran
5 Non-communicable Diseases Institute, Gut and Liver Research Center, Mazandaran University of Medical Sciences, Sari, Iran
6 Imam Khomeini Educational Hospital, Mazandaran University of Medical Sciences, Sari, Iran
doi
10.30476/mejc.2024.98579.1910چکیده
Colorectal cancer (CRC) ranks as the third most prevalent cancer worldwide and is a leading cause of cancer-related mortality. Since many colon cancers present no significant clinical symptoms, identifying new biomarkers or a set of biological indicators significant for clinical trials is crucial for the early detection of CRC. This advancement also aids in establishing new objectives for interventional therapeutic strategies against the disease. Currently, research is exploring various proteins, glycoproteins, and cellular and humoral substances involved in cellular homeostasis mechanisms as potential cancer markers. This review examines the potential utility of fucosylation and sialylation processes, as well as sex hormones, as biomarkers in the diagnosis and prognosis of CRC. A comprehensive search was conducted in PUBMED, MEDLINE, and Google Scholar, supplemented by a manual search of relevant journals. The keywords were L-fucose, sialic acid, fucosyltransferase-4, galectin-3, and steroid hormones in CRCs.
